Literature DB >> 22968736

[Meeting report of the working group on Uropathology].

A Hartmann1, R Knüchel-Clarke.   

Abstract

Mesh：

Year:  2012        PMID： 22968736     DOI： 10.1007/s00292-012-1686-5

Source DB:  PubMed          Journal:  Pathologe        ISSN： 0172-8113            Impact factor:   1.011


× No keyword cloud information.
  3 in total

1.  A specific gene expression signature characterizes metastatic potential in clear cell renal cell carcinoma.

Authors:  Jimsgene Sanjmyatav; Thomas Steiner; Heiko Wunderlich; Julia Diegmann; Mieczyslaw Gajda; Kerstin Junker
Journal:  J Urol       Date:  2011-05-20       Impact factor: 7.450

2.  An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

Authors:  Viktor Grünwald; Pierre I Karakiewicz; Sevil E Bavbek; Kurt Miller; Jean-Pascal Machiels; Se-Hoon Lee; James Larkin; Petri Bono; Sun Young Rha; Daniel Castellano; Christian U Blank; Jennifer J Knox; Robert Hawkins; Oezlem Anak; Marianne Rosamilia; Jocelyn Booth; Nicoletta Pirotta; István Bodrogi
Journal:  Eur J Cancer       Date:  2011-07-29       Impact factor: 9.162

3.  Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.

Authors:  E Herrmann; N Marschner; M O Grimm; C H Ohlmann; U Hutzschenreuter; F Overkamp; M Groschek; K Blumenstengel; G Pühse; T Steiner
Journal:  World J Urol       Date:  2011-04-03       Impact factor: 4.226
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.